Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 552-554

  Moses, Robert G ^a  

^a Illawarra Diabetes Service   (Australia)

Author keywords

glycosylated hemoglobin; HbA1c; metformin; repaglinide; type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; METFORMIN; REPAGLINIDE; SITAGLIPTIN;

ARTICLE; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 41849147193     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.007     Document Type: Article

References (7)

1. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. [published correction appears in Diabetes Care. 2006;449:22816 -2818]. Diabetes Care 29 (2006) 1963-1972
2. Quality and outcomes framework guidance (2006) [British Medical Association Web site]. http:////wwww.bbma.org.uk/ ap.nsf/Content/qof06~summclinical.Accessed October 18, 2007.
3. Moses R., Slobodniuk R., Boyages S., et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22 (1999) 119-124
4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus (PP Statement). Diabetes Care 221 Suppl 1 (1998) S23-S31
5. Raskin P., Klaff L., McGill J., et al., Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin. [published correction appears in Diabetes Care . 2003;226:22708 ]. Diabetes Care 226 (2003) 2063-2068
6. Charbonnel B., Karasik A., Liu J., et al., Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 229 (2006) 2638-2643
7. 1c. Diabetes Care 26 (2003) 881-885